Hospitalization and Mortality in Patients with Hypertrophic Obstructive Cardiomyopathy treated with Mavacamten between April 2022 and October 2024

Author Information

David Murillo, Division of Cardiology, Department of Medicine, Reading Hospital-Tower Health, West Reading, PAFollow
Christopher Reggio, Division of Cardiology, Department of Medicine, Reading Hospital-Tower Health, West Reading, PA
Muhammad Asad Hanif, Department of Cardiology, Reading Hospital – Tower Health, West Reading, PA
Ghazi Mirrani, Division of Cardiology, Department of Medicine, Reading Hospital-Tower Health, West Reading, PA
Jared Green, Division of Cardiology, Department of Medicine, Reading Hospital-Tower Health, West Reading, PA

Keywords:

Hypertrophic cardiomyopathy, Mavacamten, Hospitalization, ICU admission, Mortality

Recommended Citation

Murillo, David; Reggio, Christopher; Hanif, Muhammad Asad; Mirrani, Ghazi; and Green, Jared, "Hospitalization and Mortality in Patients with Hypertrophic Obstructive Cardiomyopathy treated with Mavacamten between April 2022 and October 2024" (2025). Tower Health Research Day. 1.
https://scholarcommons.towerhealth.org/th_researchday/2024-2025/in_person_posters/1

Institutional Review Board/Institutional Animal Care and Use Committee Approved or Exempt

Not Applicable